Dana-Farber Cancer Institute
Avatar

Study of Abemaciclib for Patients with RB-Positive, Triple Negative Metastatic Breast Cancer

By Dana-Farber Cancer Institute FEATURING Shom Goel
By Dana-Farber Cancer Institute FEATURING Shom Goel
918 views
April 1, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

03:38
Lilly Medical Affairs

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri

Featured Video

03:15
Lilly Medical Affairs

Unmet Needs and Resistance Mechanisms in Patients With HR+, HER2- MB…

Feat. W. Mchayleh

Recommended

AUTOPLAY
25:08

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

4.0K views

5 months ago
12:14

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.0K views

4 months ago
11:31

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, TROPI…

Insights from 2023 ASCO® Annual Meeting

P. Tarantino

8.2K views

1 year ago
10:53

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

2.1K views

3 months ago
07:23

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Total Health

R. O'Regan

1.3K views

8 months ago
12:35

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+ mBC?"

Insights from 2023 SABCS

S. Tolaney, H. Rugo

3.0K views

10 months ago
14:16

Year in Review: Breast Cancer

Dana-Farber Cancer Institute

P. Tarantino

2.4K views

9 months ago
17:12

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

1.5K views

2 months ago
14:52

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

681 views

1 month ago
17:50

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.8K views

6 months ago
28:36

ASCO® 2023 Summary: "eBC Expert Panel Discussion on Key Trials Inclu…

Insights from 2023 ASCO® Annual Meeting

H. Rugo, K. Jhaveri

4.8K views

1 year ago
36:18

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Insights from ESMO Breast 2024 Annual Meeting

H. Rugo

1.2K views

5 months ago
17:20

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNOTE-75…

Insights from 2023 ESMO Annual Meeting

P. Tarantino

2.1K views

1 year ago
27:01

CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC

Scripps Health

S. Sammons

1.7K views

7 months ago
33:44

ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive & Clini…

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

915 views

4 months ago
22:34

What's New in Breast Cancer?

Dana-Farber Cancer Institute

S. Tolaney

1.5K views

9 months ago
10:34

ASCO® 2024 Noteworthy Abstracts in Breast Cancer

Sara Tolaney

H. Rugo

929 views

5 months ago
16:19

Optimizing Adjuvant Treatment in High-Risk HR+/HER2- eBC: Patient Se…

Wassim Mchayleh

864 views

3 months ago
21:01

ESMO Breast 2024 Panel Discussion: "Key Updates in Breast Cancer"

Insights from ESMO Breast 2024 Annual Meeting

S. Tolaney, H. Rugo

908 views

5 months ago
38:49

ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522…

2024 ESMO Annual Meeting Insights Hub

S. Tolaney, H. Rugo

493 views

1 month ago